Lannett Company, Inc. a manufacturer of generic pharmaceuticals, announced that Cody Laboratories (Cody), a manufacturer/supplier of bulk active pharmaceutical ingredients (API), has received approval from the United States Patent and Trademark Office for its patent (US 7,399,859 B1) regarding a method for the preparation of Hydromorphone and Hydrocodone. 

Hydromorphone is a centrally-acting analgesic drug of the opioid class and a derivative of Morphine. Hydrocodone is an opioid derived pain management product and the most prescribed generic drug in the United States.

"Our patented method for preparing Hydromorphone and Hydrocodone will greatly enhance our ability to manufacture these products quickly and efficiently," said Arthur Bedrosian, president and chief executive officer of Lannett. "Importantly, with minimal incremental investment, the faster manufacturing time appreciably expands our manufacturing capacity, allowing us to maximize our production assets. The approval of this patent is a testament to the hard work of our colleagues at Cody, and we are excited to reap the rewards from this new method of manufacturing these widely prescribed pharmaceuticals. As we enter the pain management market, we take seriously our responsibilities with regard to the secure manufacture and distribution of prescription narcotics."